The South-Eastern Norway Regional Health Authority (HSØ) will from 2025 fund a new 3y postdoc position in Munthe’s team to work on adoptive cell therapy of tumor infiltrating lymphocytes for metastatic sarcoma, and a 3y PhD position in Andersen's team to develop a new vaccine technology platform.
Jan Terje Andersen, Ludvig Munthe and Thea Våtsveen each receives 500 000 NOK from Kreftforeningen for Qualification Projects. Andersen for designing a new tailored antibody-format to target cancer, and Munthe and Våtsveen for new drug actions targeting LTK in chronic lymphocytic leukemia and mantle cell lymphoma respectively.
In a qualification project, the primary objective is to thoroughly explore and pinpoint the most promising commercial application prospects, including service innovation.